Claude's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET 9TH FLOOR, BOSTON, MA, 02109.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over 24,745,707$ worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth 3,376,410$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Advisors Llc Orbi Med Capit...、Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of 4,572,148$. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth 92,340$.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: